| 【Objective】To analyze the efficacy and safety of imatinib’s treatment in163cases with chronicphase of philadelphia-positive chronic myelogenous leukemia(Ph+CML-CP).【Methods】163patients(male108female55) with Ph+CML-CP were treated with imatinib400mg(n=161)or200mg(n=2)once daily for more than one year. All the163caseshematologic response,cytogenetic response and molecular response were analyzed.【Results】With a median follow-up of50（12~103）months,complete hematologic response（CHR）rate was98.64%%,cytogenetic response（CyR）rate81.73%,completecytogenetic response（CCyR）rate70.19%,complete molecular response （CMR）rate63.16%.The progression free survival(PFS) rate of the1st，2nd，3rd，4th and5thyear were98.8%，92.0%，86.7%，83.4%，82.0%.The Overall Survival(OS) rate of1st，2nd，3rd，4th and5th year were99.4%，97.9%，97.1%，93.7%，92.3%.Grade3leukocytopenia occurred in12.36%of the patients, Grade3thrombocytopeniaoccurred in20%of the patients.Both grade4leukocytopenia and grade4thrombocytopenia occurred in2patients.Multivariate analysis showed that grade3and grade4thrombocytopenia（P=0.003RR=3.509）and weather to take imatinib inthree month after diagnosed （P=0.013RR=3.505）were independent influencingfactors for PFS;Grade3and4leukocytopenia was independent influencing factors forOS(P=0.012RR=7.752).The initial white blood cell count（P=0.048RR=1.774）and Grade3and4leukocytopenia （P=0.002RR=6.285） were independentinfluencing factors for CMR rate;The platelet count（P=0.045RR=3.346）beforetherapy was independent influencing factors for the time to get CMR.The time to take imatinib after diagnosed （P=0.003RR=3.692）was independent influencing factorsfor Grade3and4thrombocytopernia;The white blood cell count(P=0.049RR=1.692) was independent influencing factors for grade3and4thrombocytopenia.【Conclusion】Imatinib significantly improves cytogenetic response rate, molecular responserate, progression free survival and overall survival for Ph+CML-CP patients.Imatinibwas better tolerated than combination therapy. |
PDF Full Text Request